share_log

昊海生科获民生证券买入评级,“并购+研发”助推医美业务再上新台阶

JRJ Finance ·  May 13, 2024 13:28

5月13日,昊海生科获民生证券买入评级,近一个月昊海生科获得4份研报关注。

研报预计公司产品覆盖眼科、医美、骨科、防粘连等领域,眼科产品力强,增长稳健,骨科及防粘连业务发展稳定,医美业务在高增长的高端玻尿酸领域重点布局,有望拉动公司收入快速增长。预计2024-2026年公司实现营收32.62亿元、39.87亿元、48.13亿元,同比+22.9%,+22.2%,+20.7%;归母净利润为5.34亿元、6.65亿元、8.19亿元,同比+28.2%,+24.7%,+23.1%。研报认为,昊海生科过去一年的收盘价与市盈率的变动,主要系医药业务稳健增长的同时,通过“内生增长+外延并购”使医美业务进入快速上升通路,拉动收入与利润高增长。

风险提示:新产品开发失败的风险、医药行业监管政策变化带来的风险、核心技术泄密和核心技术人员流失的风险。

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 363

Recommended

Write a comment

Statement

This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.